DETD-35

• Description :

  DETD-35 is an inhibitor of the MEK-ERK, Akt, and STAT3 signaling pathways, which promotes cancer cell apoptosis (Apoptosis) and reduces cancer cell resistance to Vemurafenib (HY-12057) . The IC50 values of DETD-35 against wild-type and mutant melanoma cell lines B16-F10, MeWo, SK-MEL-2, A2058c, and A375c are 2.7, 6.0, 3.9, 3.1, and 2.5 μM, respectively. DETD-35 holds promise for research in the field of anti-melanoma therapy[1].

• UNSPSC :

  12352005

• Target :

  Akt; Apoptosis; ERK; STAT

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; JAK/STAT Signaling; MAPK/ERK Pathway; PI3K/Akt/mTOR; Stem Cell/Wnt

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/detd-35.html

• Smiles :

  O=C(O[C@H]1[C@H](C(C(O2)=O)=C)[C@@H]2CC(C(O3)=O)=C[C@H]3C/C(C)=C/1)CC4=CC=CC5=C4C=CC=C5

• Molecular Formula :

  C27H24O6

• Molecular Weight :

  444.48

• References & Citations :

  [1]Feng JH, et al. A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice. Mol Cancer Ther. 2016 Jun;15 (6) :1163-76.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  STAT3

• CAS Number :

  [1836209-98-3]